Shares of Eli Lilly gains momentum on news of an FDA drug approval. CNBC's Seema Mody reports.
Kara Swisher, Recode executive editor, shares her take on the Theranos board, calling it "the most unusual board in Silicon Valley."
Jim Cramer says investors need to be careful in high-risk cancer immunotherapy stocks.
CNBC's Meg Tirrell speaks to Brent Saunders, Allergan CEO, about the drug industry's new era under a Trump presidency.
CNBC's Meg Tirrell speaks to Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, about Trump's effect on biotech, drug pricing and the study against high cholesterol.
CNBC's Meg Tirrell speaks to Robert Nelsen, ARCH Venture Partners founder, about Trump's potential impact on the drug industry, and the future of biotech.
Billionaire Steven A. Cohen's former hedge fund SAC Capital Advisors has agreed to pay $135 million to resolve a lawsuit.
Sources say the Valeant-Takeda deal is "all but dead." CNBC's Scott Wapner reports the details, as well as how the market is reacting to this news.
Christopher Weaver, Wall Street Journal reporter, discusses Theranos' "smart money" investors, as well as the company's recent challenges.
WASHINGTON— Two of the Senate's most liberal lawmakers are assailing a $6.3 billion medical research bill as a gift to drug companies, even as Republican leaders prepare to try pushing the measure through the lame-duck Congress. "It's time for Congress to stand up to the world's biggest pharmaceutical companies, not give them more handouts," Sen.
As Congress began the final stretch of its post-election session, Warren said the 996- page measure— a top priority for GOP leaders and backed by the biomedical industry— was riddled with provisions that she called "a bunch of special giveaways" to big pharmaceutical companies. "They didn't send us here to whimper, whine or grovel," she said on the Senate floor about...
Jason Kolbert, Maxim Group, and Les Funtleyder, ESquared, discuss biotech opportunities in Cuba post-Castro.
Thernos is being sued for alleged fraud by Robert Colman, Robertson Stephens co-founder. CNBC's Sue Herera reports.
Alex Tarrant, assistant editor at Dealreporter Europe, weighs in on Johnson & Johnson's proposed acquisition of Swiss biotechnology company Actelion.
Robyn Karnauskas, Citi Research lead biotech analyst, weighs in on the drop in Juno Therapeutics following the company's study halt.
The “Fast Money Halftime Report” traders weigh in on the biotech sector, with Eli Lilly and Juno Therapeutics stocks dropping significantly.
If they're right, the average lifespan of 79 years will be a thing of the past, and humans could live for decades longer.
CNBC's Meg Tirrell reports the latest surrounding the Valeant and Philidor controversy. CNBC's Kate Kelly and David Winters, Wintergreen Advisors CEO, weigh in on Valeant's stock.
Amgen's migraine drug meets its clinical trial goal. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell on the latest regarding data on how a Puma drug designed to treat breast cancer shows gastric side effects.